Joan Guitart, MD
Dermatopathology · Chicago, ILNPI 1225074727
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $40,450 of the $43,401 with a category attached, or 93.2%. Kyowa Kirin, Inc. accounts for 79.6% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2023 at $21,170 and has fallen 99.6% since, to $86 in 2025.
Across 40 payments — averaging $1085.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kyowa Kirin, Inc.$35K
- Helsinn Therapeutics (U.S.), Inc.$9K
- Sanofi$36
- Tempus AI, Inc$32
- Pfizer$15
- Incyte Corporation$13
Across 2 payments — averaging $1250.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- LEO Pharma AS$3K
What the payments were for
- Consulting fees$40,45093%
- Travel & lodging$1,7724%
- Food & beverage$1,1273%
- Education$510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kyowa Kirin, Inc. | 22 | $34,567 |
| Helsinn Therapeutics (U.S.), Inc. | 14 | $8,738 |
| Sanofi | 1 | $36 |
| Tempus AI, Inc | 1 | $32 |
| Pfizer | 1 | $15 |
| Incyte Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few dermatopathology providers in Illinoisto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PegasysPeginterferon Alfa-2a | 62 | $271,835 |
| Bexarotene | 39 | $158,978 |
| ValchlorMechlorethamine Hcl | 16 | $99,283 |
| Acitretin | 193 | $33,359 |
| Triamcinolone Acetonide | 89 | $1,476 |
| Fluocinonide | 26 | $928 |
| Clobetasol Propionate | 19 | $721 |
| MethotrexateMethotrexate Sodium | 47 | $380 |
| Ketoconazole | 19 | $183 |
| Levothyroxine Sodium | 22 | $161 |
| Rosuvastatin Calcium | 11 | $95 |
| Gabapentin | 23 | $91 |
| Mupirocin | 17 | $67 |
Paid to pharmacies, not to this prescriber.
Other dermatopathology in Chicago
- Vesna Petronic RosicChicago$11K
- Kayla St ClaireChicago$4K
- Kyla Price-JaureguiChicago$2K
- Cuong NguyenChicago$413
- Sara Kullberg PearsonChicago$150
- Lohini SundharkrishnanChicago$52
- Brian NickoloffMaywood$116K
- George NahassGlen Carbon$5K
- Carl SoderstromPeoria$385
- Suzanne BirminghamElgin$244
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.